Relay Therapeutics Prices Public Offering at $12 per Share
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 31 minutes ago
0mins
Should l Buy RLAY?
Source: Newsfilter
- Offering Size: Relay Therapeutics announced a public offering of 22,916,667 shares at $12.00 per share, with gross proceeds expected to be approximately $275 million before underwriting discounts, which will significantly bolster the company's funding for future R&D initiatives.
- Underwriter Arrangement: The offering is being managed by Jefferies, TD Cowen, Goldman Sachs, and Guggenheim Securities as joint book-running managers, with Raymond James as the lead manager, reflecting strong market confidence in Relay's growth prospects and strategic direction.
- Registration Statement: The offering is conducted under an automatically effective shelf registration statement on Form S-3ASR filed with the SEC on August 6, 2024, ensuring compliance and transparency, which is likely to attract more investor participation.
- Closing Timeline: The offering is expected to close on or about May 22, 2026, and if successful, will provide Relay Therapeutics with essential capital to advance its innovative drug development efforts in cancer and genetic diseases.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RLAY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RLAY
Wall Street analysts forecast RLAY stock price to rise
6 Analyst Rating
5 Buy
1 Hold
0 Sell
Strong Buy
Current: 12.070
Low
13.00
Averages
14.75
High
17.00
Current: 12.070
Low
13.00
Averages
14.75
High
17.00
About RLAY
Relay Therapeutics, Inc. is a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease. The Company's Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The Company's lead clinical asset, zovegalisib (RLY-2608), is the pan-mutant selective PI3Ka inhibitor to enter clinical development and is currently in a Phase 3 clinical trial (ReDiscover-2) in HR+/HER2- metastatic breast cancer. Zovegalisib is also being investigated in a group of genetic disease indications called PI3Ka-driven vascular anomalies. Its pipeline also includes programs for NRAS-driven solid tumors and Fabry disease.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Relay Therapeutics Prices Public Offering at $12 per Share
- Offering Size: Relay Therapeutics announced a public offering of 22,916,667 shares at $12.00 per share, with gross proceeds expected to be approximately $275 million before underwriting discounts, which will significantly bolster the company's funding for future R&D initiatives.
- Underwriter Arrangement: The offering is being managed by Jefferies, TD Cowen, Goldman Sachs, and Guggenheim Securities as joint book-running managers, with Raymond James as the lead manager, reflecting strong market confidence in Relay's growth prospects and strategic direction.
- Registration Statement: The offering is conducted under an automatically effective shelf registration statement on Form S-3ASR filed with the SEC on August 6, 2024, ensuring compliance and transparency, which is likely to attract more investor participation.
- Closing Timeline: The offering is expected to close on or about May 22, 2026, and if successful, will provide Relay Therapeutics with essential capital to advance its innovative drug development efforts in cancer and genetic diseases.
See More
Relay Therapeutics Shares Surge 8% Following Positive Analyst Ratings and Drug Results
- Positive Clinical Results: Relay Therapeutics announced that 60% of patients responded to the Phase 2 trial of zovegalisib at 12 weeks, significantly exceeding analyst expectations, indicating strong potential for revenue growth in treating vascular anomalies.
- Safety and Tolerability: Nearly all patients treated with the drug experienced symptomatic improvements at the 12-week mark, demonstrating zovegalisib's good safety and tolerability profile, which lays a solid foundation for future development and market introduction.
- Equity Dilution Risk: Although the company announced a secondary stock offering potentially exceeding $200 million, which could dilute shareholder equity, this dilution is relatively minor given Relay's nearly $2.5 billion market cap, potentially alleviating investor concerns about dilution.
- Analyst Price Target Increases: Analysts from Barclays and Citizens JMP raised their price targets for Relay to $27 and $21 respectively, both maintaining buy ratings, reflecting optimistic market expectations for the company's future growth potential.
See More
Relay Therapeutics Shares Surge on Bullish Analyst Upgrades
- Stock Surge: Relay Therapeutics' shares soared nearly 8% on Wednesday following the announcement of positive Phase 2 results for zovegalisib, a drug targeting vascular anomalies, indicating strong market confidence in its potential.
- Analyst Upgrades: Peter Lawson from Barclays raised his price target from $21 to $27, while Silvan Turkcan of Citizens JMP increased his target from $19 to $21, both maintaining buy ratings, reflecting optimistic expectations for the company's future performance.
- Positive Clinical Results: The drug demonstrated a 60% response rate among tested patients at the 12-week mark, with nearly all individuals showing symptomatic improvements, highlighting both the efficacy and safety profile of zovegalisib.
- Stock Dilution Impact: Although the company plans to float a secondary offering exceeding $200 million, which could lead to some dilution, this is relatively minor given its nearly $2.5 billion market cap, and the market remains optimistic about its long-term prospects.
See More
Barclays Raises Relay Therapeutics Price Target to $27, Signaling 124% Upside
- Price Target Increase: Barclays raised its price target for Relay Therapeutics from $21 to $27 while maintaining an ‘Overweight’ rating, indicating a potential upside of 124% from Tuesday's closing price, reflecting growing confidence in zovegalisib.
- Clinical Data Support: The latest clinical update from Relay Therapeutics revealed that zovegalisib achieved a 60% volumetric response rate at 12 weeks in patients with vascular anomalies, with nearly all patients experiencing symptomatic improvement, highlighting the drug's competitive edge and market potential.
- Market Opportunity Assessment: Barclays noted that zovegalisib, as a mutant-selective cancer drug, is positioned to capture a $6 billion market opportunity among vascular anomaly patients, with limited competition and a possible accelerated regulatory pathway, enhancing its investment appeal.
- Positive Investor Sentiment: Despite Relay Therapeutics' stock declining over 5% in pre-market trading on Wednesday, retail investor sentiment on Stocktwits remained extremely bullish, indicating confidence in the company's future prospects, with a year-to-date stock increase of 43%.
See More
Relay Therapeutics Proposes $175 Million Public Offering
- Funding Initiative: Relay Therapeutics has announced a proposed public offering of $175 million aimed at financing its clinical-stage precision medicine projects, particularly the development of Zovegalisib.
- Underwriter Option: The offering includes a 30-day option for underwriters to purchase an additional 15% of the shares, which may enhance market interest in the fundraising initiative.
- Clinical Development: Zovegalisib, the first pan-mutant selective PI3Ka inhibitor to enter clinical development, is currently undergoing the Phase 3 ReDiscover trial for HR+/HER2- metastatic breast cancer, indicating the company's potential in oncology.
- Stock Price Fluctuation: Relay Therapeutics closed at $12.07 on Monday, down 0.25%, and in pre-market trading, shares fell further to $11.43, a decline of 5.30%, reflecting market caution regarding the fundraising news.
See More
Relay Therapeutics Announces $175M Underwritten Public Offering
- Funding Size: Relay Therapeutics has announced a public offering of $175 million in common stock, aimed at strengthening its capital base to support ongoing research and operational activities.
- Underwriter Option: The company plans to grant underwriters a 30-day option to purchase an additional 15% of the offered shares, a strategy that could further increase total funding and enhance market confidence.
- Market Reaction: Following the release of mid-stage trial data, Relay Therapeutics' stock has shown positive performance, indicating investor recognition of its lead asset's potential in vascular anomalies, which may create a favorable environment for this financing.
- Strategic Implications: This funding will provide the necessary capital to advance the company's research in areas such as breast cancer and vascular anomalies, further solidifying its position in the biopharmaceutical industry.
See More
Relay Therapeutics Prices Public Offering at $12 per Share
- Offering Size: Relay Therapeutics announced a public offering of 22,916,667 shares at $12.00 per share, with gross proceeds expected to be approximately $275 million before underwriting discounts, which will significantly bolster the company's funding for future R&D initiatives.
- Underwriter Arrangement: The offering is being managed by Jefferies, TD Cowen, Goldman Sachs, and Guggenheim Securities as joint book-running managers, with Raymond James as the lead manager, reflecting strong market confidence in Relay's growth prospects and strategic direction.
- Registration Statement: The offering is conducted under an automatically effective shelf registration statement on Form S-3ASR filed with the SEC on August 6, 2024, ensuring compliance and transparency, which is likely to attract more investor participation.
- Closing Timeline: The offering is expected to close on or about May 22, 2026, and if successful, will provide Relay Therapeutics with essential capital to advance its innovative drug development efforts in cancer and genetic diseases.
See More
Relay Therapeutics Shares Surge 8% Following Positive Analyst Ratings and Drug Results
- Positive Clinical Results: Relay Therapeutics announced that 60% of patients responded to the Phase 2 trial of zovegalisib at 12 weeks, significantly exceeding analyst expectations, indicating strong potential for revenue growth in treating vascular anomalies.
- Safety and Tolerability: Nearly all patients treated with the drug experienced symptomatic improvements at the 12-week mark, demonstrating zovegalisib's good safety and tolerability profile, which lays a solid foundation for future development and market introduction.
- Equity Dilution Risk: Although the company announced a secondary stock offering potentially exceeding $200 million, which could dilute shareholder equity, this dilution is relatively minor given Relay's nearly $2.5 billion market cap, potentially alleviating investor concerns about dilution.
- Analyst Price Target Increases: Analysts from Barclays and Citizens JMP raised their price targets for Relay to $27 and $21 respectively, both maintaining buy ratings, reflecting optimistic market expectations for the company's future growth potential.
See More
Relay Therapeutics Shares Surge on Bullish Analyst Upgrades
- Stock Surge: Relay Therapeutics' shares soared nearly 8% on Wednesday following the announcement of positive Phase 2 results for zovegalisib, a drug targeting vascular anomalies, indicating strong market confidence in its potential.
- Analyst Upgrades: Peter Lawson from Barclays raised his price target from $21 to $27, while Silvan Turkcan of Citizens JMP increased his target from $19 to $21, both maintaining buy ratings, reflecting optimistic expectations for the company's future performance.
- Positive Clinical Results: The drug demonstrated a 60% response rate among tested patients at the 12-week mark, with nearly all individuals showing symptomatic improvements, highlighting both the efficacy and safety profile of zovegalisib.
- Stock Dilution Impact: Although the company plans to float a secondary offering exceeding $200 million, which could lead to some dilution, this is relatively minor given its nearly $2.5 billion market cap, and the market remains optimistic about its long-term prospects.
See More
Barclays Raises Relay Therapeutics Price Target to $27, Signaling 124% Upside
- Price Target Increase: Barclays raised its price target for Relay Therapeutics from $21 to $27 while maintaining an ‘Overweight’ rating, indicating a potential upside of 124% from Tuesday's closing price, reflecting growing confidence in zovegalisib.
- Clinical Data Support: The latest clinical update from Relay Therapeutics revealed that zovegalisib achieved a 60% volumetric response rate at 12 weeks in patients with vascular anomalies, with nearly all patients experiencing symptomatic improvement, highlighting the drug's competitive edge and market potential.
- Market Opportunity Assessment: Barclays noted that zovegalisib, as a mutant-selective cancer drug, is positioned to capture a $6 billion market opportunity among vascular anomaly patients, with limited competition and a possible accelerated regulatory pathway, enhancing its investment appeal.
- Positive Investor Sentiment: Despite Relay Therapeutics' stock declining over 5% in pre-market trading on Wednesday, retail investor sentiment on Stocktwits remained extremely bullish, indicating confidence in the company's future prospects, with a year-to-date stock increase of 43%.
See More
Relay Therapeutics Proposes $175 Million Public Offering
- Funding Initiative: Relay Therapeutics has announced a proposed public offering of $175 million aimed at financing its clinical-stage precision medicine projects, particularly the development of Zovegalisib.
- Underwriter Option: The offering includes a 30-day option for underwriters to purchase an additional 15% of the shares, which may enhance market interest in the fundraising initiative.
- Clinical Development: Zovegalisib, the first pan-mutant selective PI3Ka inhibitor to enter clinical development, is currently undergoing the Phase 3 ReDiscover trial for HR+/HER2- metastatic breast cancer, indicating the company's potential in oncology.
- Stock Price Fluctuation: Relay Therapeutics closed at $12.07 on Monday, down 0.25%, and in pre-market trading, shares fell further to $11.43, a decline of 5.30%, reflecting market caution regarding the fundraising news.
See More
Relay Therapeutics Announces $175M Underwritten Public Offering
- Funding Size: Relay Therapeutics has announced a public offering of $175 million in common stock, aimed at strengthening its capital base to support ongoing research and operational activities.
- Underwriter Option: The company plans to grant underwriters a 30-day option to purchase an additional 15% of the offered shares, a strategy that could further increase total funding and enhance market confidence.
- Market Reaction: Following the release of mid-stage trial data, Relay Therapeutics' stock has shown positive performance, indicating investor recognition of its lead asset's potential in vascular anomalies, which may create a favorable environment for this financing.
- Strategic Implications: This funding will provide the necessary capital to advance the company's research in areas such as breast cancer and vascular anomalies, further solidifying its position in the biopharmaceutical industry.
See More
